February 2025

Recruitment Pharmaceutical Sciences candidates at IMTECH
16 February 2025

Recruitment Pharmaceutical Sciences candidates at IMTECH - 12 vacancies

Towards discovery and development of novel drugs and Pharmaceuticals; Masters, Integrated Masters in Natural or Agricultural or Pharmaceutical Sciences, MVSc, Animal Sciences OR Bachelors degree in Engineering or Technology or Medicine from a recognized University. Experience in handling microbes, identification, characterization and preservation. Knowledge and exposure to molecular biology techniques i.e. DNA isolation, PCR etc will be an asset. Experience in microbial genomics and metagenomics
16 February 2025
Life Sciences, Biotechnology recruitment in J C Bose Fellowship at RCB
Doctoral Degree and Masters degree in Life Sciences, Biotechnology and two years research experience and knowledge of virology and molecular biology as demonstrated by research publications. Experience of high throughput screening in cultured cells. 
16 February 2025
CFTRI invites online applications for Scientist Post | Pay Matrix Rs.67,700 - 2,08,700
To carry out R&D activities in the area of Nutraceutical/Functional Foods for their health benefits To provide pharmacology support in the design and execution of preclinical and clinical efficacy studies; Experience in in-vitro and in-vivo pharmacology, experimental pharmacology techniques related to various animal models and pharmacokinetic studies. Research contributions evidenced by peer-reviewed publications in SCI journals or patents.
16 February 2025
NIPGR looking for Project Scientist - Salary Rs. 56000 plus HRA pm
Candidates having M.Tech Engineering or Technology or Ph.D degree awarded in Life Sciences, Biotechnology, Plant Molecular Biology or any other related field and fulfilling the guidelines, norms of DST Office Memorandum dated July 10, 2020 are eligible to apply. The candidate should have research experience in Bioinformatics.
16 February 2025
Advertisement for M.Pharm, MSc, MTech under Research Project at Tata Medical Center
NEO - HYPORT, Does Neoadjuvant radiotherapy NART improve breast cancer outcomes. Tata Medical Center, Kolkata, is a state-of-the-art tertiary Comprehensive Cancer Care Center being established to serve the needs of society in the eastern part of India.
15 February 2025
Opportunity for Pharmaceutical Sciences to Join NDTL as Scientist
Plan the new areas in the growing field of analytical testing in the field of Human Doping. Oversee the refinement of the existing analytical techniques as per WADA directions, from time to time, in respect of the specialties, sub- specialties handled by the NDTL.
15 February 2025
Pharma and Life Sciences Recruitment as Clinical Trial Coordinator at MPMMCC
Graduate in Life Science, B.Pharmacy with Diploma in Clinical Research. Relevant experience in clinical research.
15 February 2025
Interview for M.Pharm, B.Pharm, MSc in QC, IPQA, ADL at Concord Biotech

Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Concord, founded in the year 2000 has transformed from a single-product company to a broad-spectrum solution provider, offering products across diversified therapeutic segments.

WALK IN INTERVIEW

15 February 2025
BMS melanoma drug failed in clinical trial
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag nivolumab and relatlimab-rmbw for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival.
15 February 2025
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA talazoparib, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI enzalutamide, an androgen receptor pathway inhibitor ARPI, demonstrating a statistically significant and clinically meaningful improvement in overall survival OS compared to placebo plus XTANDI in patients with metastatic castration-resistant prostate cancer mCRPC, with or without homologous recombination repair HRR gene mutations.